Skip to content

Yes, everyone is tired of worrying about COVID-19, and with rising cases across the US it's difficult to see evidence that the population in general is trying to be any more careful now that recommendations have replaced mandates. Pediatric healthcare providers still need to be vigilant.

Another Note on Monkeypox

No, it's not the next pandemic in terms of massive transmission like SARS-CoV-2, but it is a global problem. This past week I was involved with 2 events illustrating that front-line providers need to be prepared.

First I fielded emails and calls from a pediatric practice in Maryland. A toddler who had returned from a stay in West Africa had presented to the office with sores around the mouth. The clinical history including progression of lesions and associated symptoms, plus the rash appearance, was strongly suggestive of monkeypox in my assessment. How to go from there?

First step: ensure patient is medically stable, not needing emergent care, and child and parent are in an exam room with the door closed. Don't allow staff to enter without permission, and anyone who does need to enter must don gown, gloves, and mask, preferably N95 mask. Then, call for help/advice. I was able to help a bit by calling the Maryland DOH provider phone line, and after a few minute wait got a call back. The DOH took it from there and last I heard was going to arrange for sample collection at the family's home. The child and parent exited through the back door of the office, not through the waiting room. I don't know what happened subsequently, but I did provide the pediatrician with links to information about exposure management for the office staff, while they await word on whether preliminary evaluation determines that this is truly a monkeypox PUI (Person Under Investigation).

The second instance, 2 days later, was a text from one of my ID colleagues, again regarding a toddler in a pediatric office in Maryland. The photo looked very much like monkeypox to me, although the exact epidemiology and other details weren't available at that time. My colleague was planning to go through the same procedures as above.

I mention this not to alarm but to reinforce to providers to be prepared to act on this type of scenario. Have in mind how you would "phone a friend" for advice and be sure you know your local health department's provider access details. This will save you and your staff a lot of worry and ensure your patients and families get the care they need.

Omicron Subvariants Continue to Spread

I shouldn't be surprised by now, but it is quite remarkable how SARS-CoV-2 variants continue to evolve to evade prior immunity and spread so easily. Consider the most recent US data:

The BA.2.12.1 omicron subvariant quickly took over the landscape from its BA.2 parent.

In spite of all the US cases and rapid spread, we still aren't seeing a large uptick in hospitalizations:

The same seems to be true in South Africa, where BA.4 and BA.5 reign, and also in the UK. This at least is encouraging. Let's hope we continue to receive relatively good news about hospitalizations and deaths.

Oh, and I learned something new about the whole ostrich/head in sand thing. It turns out that is a complete myth, dating back to Pliny the Elder!

My local weather hasn't been to my liking recently. I don't mind a little rain, but I want my May weather to be warm and sunny most of the time. I'd love it if SARS-CoV-2 would act a little sunnier too, but not sure this is the case.

The COVID-19 Winds

Hospitalizations in the US are clearly increasing, though not to the point yet that we could call this a true surge or wave. This is happening as we continue to see the BA.2.12.1 occupying a bigger piece of the pie across our country.

(Red is BA.2.12.1, pink is BA.2)

Looking ahead, however, we still need to keep our eyes on BA.4 and BA.5 subvariants, with South Africa being the main source of advance data along with wastewater monitoring worldwide. It's still a little early to see what's going on in South Africa, but some recent data suggests that these 2 subvariants have a great advantage in growth compared to prior variants and subvariants. A report from the UK has a nice assessment summary showing that the 2 new subvariants have a significant advantage in immune evasion that will be evidenced by increasing infection rates among both immunized and previously infected individuals as well as possibly changing effectiveness of monoclonal antibodies for therapy and prevention.

You can get a sense of how the research is moving from a preprint (non-peer reviewed) manuscript posted recently. It is laboratory modelling from structural analysis and pseudovirus neutralization assays, both helpful and relatively reliable in the past but could vary from what eventually happens in the real world. Again, time will tell.

Why Not Say It Clearly?

I stole this title from a book, apparently now out of print, that I read long ago to help improve my scientific manuscript writing. Not sure if it helped me, but maybe some of our friends at FDA and CDC should try to find a copy. A new article from Mayo Clinic reviewed COVID-19 vaccine explanations contained in FDA information fact sheets and from the CDC website. Short answer: it was too confusing for most of the US population to understand.

A target for such information is a 7th grade readability level that would apply to 83% of adults in the US. Utilizing validated tools they found that all documents pretty much failed; only the v-safe script achieved this grade level, and all failed on other measures. Given that we have extremely low acceptance of COVID-19 vaccines in the US, I hope that increasing attempts at effectively communicating risks and benefits will lead to better control of the virus.

I also recommend that healthcare providers at least skim this article to learn some tricks and tools for more effective communication with your patients and families.

The answer[s], my friend, [are] blowin' in the wind.